Trial intelligence / Profile preview

Calcineurin inhibitor-free interventions for prevention of graft-versus-host disease

2015-000602-18Phase 3Completed

Sponsor: National Heart, Lung, and Blood Institute
Start: Oct 2015
Modality: Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised trial of cyclosporine, methotrexate and cyclophosphamide in Acute Leukaemia (3 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Chronic GVHD/relapse-free survival. Started Oct 2015; status: completed.

Drugs

cyclosporinemethotrexatecyclophosphamide

Conditions

Acute Leukaemia

Beyond the preview

Go deeper on 2015-000602-18.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2015-000602-18.